Robert Groves, MD, leads a panel discussion surrounding risk factors related to heart disease.
This is a video synopsis/summary of a panel discussion involving Robert Groves, MD, executive vice president and chief medical officer, Banner |Aetna; Eugene E. Wright Jr, MD, consulting associate, Department of Medicine, Duke University Medical Center, and medical director for performance improvement, South Piedmont Area Health Education Center; Nancy Albert, PhD, CCNS, CCRN, CHFN, NE-BC, FAHA, FCCM, FHFSA, FAAN, associate chief nursing officer, research and innovation, and clinical nurse specialist at the Kaufman Center for Heart Failure Treatment and Recovery at the Cleveland Clinic; Nihar Desai, MD, MPH, vice chief, cardiovascular medicine at the Yale School of Medicine; and Kelly Marie Axsom, MD, medical director, Centralized Heart Failure Management Program at New York Presbyterian Hospital, and assistant professor of medicine at Columbia University Medical Center. The panel discusses updates in heart failure management, analyzing unmet needs and future considerations. Desai provides an overview of heart failure epidemiology, noting the significant burden in the US with an estimated 7 to 8 million individuals affected. Prevalence is increasing due to aging population and rise in risk factors like hypertension, kidney disease, diabetes, and valvular heart disease. There are also disparities across sex, race, and ethnicity. Albert expands on risk factors, highlighting lifestyle choices like sedentary behaviors and comorbid conditions like obesity and genetics. The panel aims to highlight key guideline updates and the evolving disease landscape regarding heart failure.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More